release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 that are
subject to risks and uncertainties. All statements, other than statements
of historical facts, regarding management's expectations, beliefs, goals,
plans or Memory Pharmaceuticals' prospects, future financial position,
future revenues and projected costs should be considered forward-looking.
Readers are cautioned that actual results may differ materially from
projections or estimates due to a variety of important factors, including
the outcome of clinical trials of Memory Pharmaceuticals' drug candidates
and whether they demonstrate these candidates' safety and effectiveness;
the risks and uncertainties associated with: obtaining additional financing
to support Memory Pharmaceuticals' R&D and clinical activities and
operations; obtaining regulatory approvals to conduct clinical trials and
to commercialize Memory Pharmaceuticals' drug candidates; Memory
Pharmaceuticals' ability to enter into and maintain collaborations with
third parties for its drug development programs; Memory Pharmaceuticals'
dependence on its collaborations and its license relationships; achieving
milestones under Memory Pharmaceuticals' collaborations; Memory
Pharmaceuticals' dependence on preclinical and clinical investigators,
preclinical and clinical research organizations, manufacturers and
consultants; protecting the intellectual property developed by or licensed
to Memory Pharmaceuticals; and Memory Pharmaceuticals' ability to maintain
listing on the Nasdaq Capital Market. These and other risks are described
in greater detail in Memory Pharmaceuticals' filings with the Securities
and Exchange Commission. Memory Pharmaceuticals may not actually achieve
the goals or plans described in its forward-looking statements, and
investors should not place undue reliance on these statements. Memory
Pharmaceuticals disclaims any intent or obligation to update any
forward-look
'/>"/>SOURCE Memory Pharmaceuticals Corp. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 Related medicine news :1.
Memory Pharmaceuticals to Announce Third Quarter 2008 Results on Thursday, November 13, 20082.
Leading London Neurosurgeon, Sim Farar, Partners with Los Angeles Fitness Guru to Help Baby Boomers Decrease Memory Loss 3.
Alzheimers Foundation of America Offers Free Memory Screenings Nationwide4.
Memory Pharmaceuticals Announces Issuance of Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 639085.
Help Employees Boost Memory, Lose Weight, Get Healthier & Increase Productivity6.
Circadian Rhythm Plays Role in Memory 7.
Caribou Coffee Honors Memory of One of Its Own With Amys Blend8.
Hub of fear memory formation identified in brain cells9.
Whole brain radiation increases risk of learning and memory problems in cancer patients10.
New Brain Fitness Program to Fight Memory Loss11.
Exercise May Help Prevent Age-Related Memory Loss